Peptide Therapies for Injuries Reviewed — What Works and What's Risky
A new review maps approved vs. gray-market peptides in sports medicine, flagging scarce human safety data behind widely marketed compounds.
Summary
Peptides — short amino acid chains sitting pharmacologically between small molecules and large proteins — are booming in sports medicine. Patients increasingly seek them for faster injury recovery and performance gains. This 2026 narrative review from the Performance Medicine Institute examines twelve peptides, including BPC-157, CJC-1295, TB-500, sermorelin, and FDA-approved tesamorelin, comparing their mechanisms, safety profiles, and regulatory standing. While several unapproved peptides show promising tissue-repair and metabolic results in animal studies, rigorous human safety trials are largely absent. The authors also highlight how social media amplifies placebo effects, inflating perceived efficacy. The review offers physicians a practical framework for evidence-based patient conversations about peptide use.
Detailed Summary
Peptide therapies have moved from niche biohacking circles into mainstream sports medicine clinics, fueled by patient demand and aggressive direct-to-consumer marketing. Yet the regulatory landscape is sharply divided: a handful of peptides have cleared rigorous FDA approval processes, while a large gray market of unapproved compounds operates with minimal oversight. Understanding which is which — and what the evidence actually supports — is increasingly critical for clinicians.
This narrative review by Mendias and Awan examines twelve peptides frequently marketed for musculoskeletal healing and athletic performance: AOD-9604, BPC-157, CJC-1295, FS-344 (follistatin-344), GHK-Cu, ipamorelin, MOTS-C, sermorelin, SS-31 (elamipretide), tesamorelin, Tβ4 (thymosin beta-4), and TB-500. For each, the authors assess pharmacological mechanisms, available safety data, and current regulatory status.
A consistent theme emerges: unapproved peptides frequently demonstrate favorable outcomes in preclinical animal models — including accelerated tissue repair and improved metabolic parameters — but transition to robust human clinical evidence has not occurred. Human safety data are scarce, and the authors caution that serious adverse effects remain a real possibility given unknowns around dosing, purity, and long-term exposure in unregulated preparations.
The review also addresses two underappreciated factors shaping perceived peptide efficacy. First, the placebo effect is identified as a meaningful mediator of outcomes, particularly in pain and recovery contexts. Second, social media ecosystems amplify anecdotal success stories, creating feedback loops that inflate confidence in compounds lacking clinical validation.
For physicians, the authors provide a practical decision-making framework to guide patient discussions, emphasizing evidence-based alternatives where they exist. The review serves as a timely reference as peptide use continues to grow among athletes and longevity-focused patients seeking musculoskeletal optimization.
Key Findings
- Most unapproved peptides show tissue-repair promise in animal models but lack rigorous human safety or efficacy data.
- A gray market of peptides operates largely outside regulatory oversight, posing serious patient safety risks.
- Social media amplifies the placebo effect, inflating perceived benefits of unproven peptide compounds.
- Only tesamorelin among reviewed peptides holds FDA approval; others including BPC-157 and TB-500 are unapproved.
- Authors provide a clinical framework to guide evidence-based patient conversations about peptide therapies.
Methodology
This is a narrative review, not a systematic review or meta-analysis, meaning study selection was not exhaustive or protocol-driven. The authors draw on published pharmacology, preclinical, and available clinical literature for each peptide. No original data were collected.
Study Limitations
The review is narrative rather than systematic, introducing potential selection bias in which studies and compounds were emphasized. Only the abstract was available for this analysis, limiting assessment of the full evidence synthesis. Human clinical trial data for most discussed peptides remain sparse, so conclusions about efficacy are largely extrapolated from animal research.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.